NICE recommends Celgene’s Revlimid to treat myelodysplastic syndromes

The UK National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Celgene's Revlimid (lenalidomide) to treat myelodysplastic syndromes (MDS).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news